|
|
| Maladies Infectieuses > Etude de marché sectorielle |
| Stakeholder Insight: Hepatitis in China - Liver Let Die? |
|
|
|
|
€ 12 920,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2005 |
Taille du document : |
310 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Antivirals Market Outlook: Market analysis of future growth and leading players by sector
178 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Antivirals Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provides an |
2 443,75 €
|
| |
| |
Lower Detection Limits of HBV DNA Assays
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Lower Detection Limits of HBV DNA Assays
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
HIV/AIDS Testing
340 pages | Octobre 2005 |
This report analyzes the worldwide markets for HIV/AIDS Testing in Thousands of Units.
The Product segments analyzed include HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Moni |
2 308,00 €
|
| |
| |
Pipeline Insight: Hepatitis C - Small Molecules, Big Revolution
237 pages | Avril 2005 |
IntroductionLess than 50% of chronically infected hepatitis C patients do not benefit from the current standard of care, pegylated interferon plus ribavirin.
In the short-term, the treatment landsc |
9 120,00 €
|
| |
| |
Monoclonal Antibody Therapies: Sector Analysis Tool
pages | Avril 2005 |
IntroductionThe mAb Sector Analysis Tool presents the marketed and R&D portfolios, technology focus and product development strategies of over 100 key players in the mAbs market.
In addition, you c |
6 080,00 €
|
| |
| |
Recommendations for Diagnostic Testing for Hepatitis B
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Chinese Markets for HIV Drugs
190 pages | Janvier 2003 |
China's demand for HIV drugs has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trend |
2 835,00 €
|
| |
| |
Pipeline Insight: Hepatitis B - New Kids on the Block
211 pages | Avril 2005 |
IntroductionAccording to the WHO, 350-400 million people are chronically infected with HBV progresses to liver cirrhosis and hepatocellular carcinoma.
Previously HBV has been treated with lamivudin |
9 120,00 €
|
| |
| |
Recommendations for Diagnostic Testing for Hepatitis C
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Stakeholder Insight: Hepatitis in China - Liver Let Die? |
|
|
Introduction
Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV vaccination, together with HBV and HCV screening have helped to reduce transmission, but continued transmission from mother to child (for HBV) and transmission via blood transfusions (HCV) means that HBV and HCV are likely to remain a problem.
Scope
Analysis of the current dynamics of the Chinese hepatitis market through primary research data from 176 physicians, supported by key opinion leaders
Identification of drivers and resistors of the Chinese hepatitis market, and how the Chinese healthcare system impacts these market-shaping factors
Examination of key hepatitis drug regimens for hepatitis in China, and factors affecting prescription trends underlying these regimens
Assessment of the differences between China and the 7 major markets in terms of HBV and HCV transmission and diagnosis
Highlights
Datamonitor physician research indicated that HBV incidence is decreasing in China. In contrast to the seven major markets, where most patients acquire HBV sexually, perinatal transmission is the dominant HBV transmission route, which impacts on HBV disease progression and effectiveness of drug therapy.
Chinese physicians believe that HCV incidence may be increasing in China. Blood transfusion is though to be the dominant HCV transmission route in China, while in the seven major markets, HCV is mainly acquired through intravenous drug use.
Chinese physicians do not consider any HBV therapy a gold-standard, although lamivudine is the most prescribed first-line therapy, while adefovir is the most prescribed second-line therapy. While treatment choice is more limited for HCV, the Chinese HCV market is highly fragmented, with treatment differing significantly between regions.
Reasons to Purchase
Review the clinical and commercial factors shaping the uptake of hepatitis products in China, and the opportunities and threats facing the market
Gain insight into HBV and HCV prevalence, transmission and coinfection in China
Evaluate unmet needs in China's hepatitis market and capitalize on these opportunities to develop commercial strategies to increase market penetration
|
|
Introduction
Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV vaccination, together with HBV and HCV screening have helped to reduce transmission, but continued transmission from mother to child (for HBV) and transmission via blood transfusions (HCV) means that HBV and HCV are likely to remain a problem.
Scope
Analysis of the current dynamics of the Chinese hepatitis market through primary research data from 176 physicians, supported by key opinion leaders
Identification of drivers and resistors of the Chinese hepatitis market, and how the Chinese healthcare system impacts these market-shaping factors
Examination of key hepatitis drug regimens for hepatitis in China, and factors affecting prescription trends underlying these regimens
Assessment of the differences between China and the 7 major markets in terms of HBV and HCV transmission and diagnosis
Highlights
Datamonitor physician research indicated that HBV incidence is decreasing in China. In contrast to the seven major markets, where most patients acquire HBV sexually, perinatal transmission is the dominant HBV transmission route, which impacts on HBV disease progression and effectiveness of drug therapy.
Chinese physicians believe that HCV incidence may be increasing in China. Blood transfusion is though to be the dominant HCV transmission route in China, while in the seven major markets, HCV is mainly acquired through intravenous drug use.
Chinese physicians do not consider any HBV therapy a gold-standard, although lamivudine is the most prescribed first-line therapy, while adefovir is the most prescribed second-line therapy. While treatment choice is more limited for HCV, the Chinese HCV market is highly fragmented, with treatment differing significantly between regions.
Reasons to Purchase
Review the clinical and commercial factors shaping the uptake of hepatitis products in China, and the opportunities and threats facing the market
Gain insight into HBV and HCV prevalence, transmission and coinfection in China
Evaluate unmet needs in China's hepatitis market and capitalize on these opportunities to develop commercial strategies to increase market penetration
|
|
|
PPLSEN
|
|
|
|
|
